Improving publication rates of biomarker results from cancer trials.
Mandatory nondiagnostic biopsies for biomarker research pose risk and inconvenience to patients with cancer that should be justified by the knowledge gained. This commentary reflects on the publication by Freeman and Kimmelman, which points to a potentially low publication rate of biomarker results from cancer clinical trials requiring nondiagnostic biopsies.
Merck Research Laboratories, North Wales, Pennsylvania 19454, USA. robert.iannone@merck.com
Robert
R
Iannone
D000970:Antineoplastic Agents / Q000494:pharmacology*; D006801:Humans; D011642:Publications; D058028:Research Report
D000970:Antineoplastic Agents